Compare TLS & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLS | NERV |
|---|---|---|
| Founded | 1969 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.4M | 301.6M |
| IPO Year | 2020 | 2014 |
| Metric | TLS | NERV |
|---|---|---|
| Price | $4.60 | $4.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $7.90 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 904.5K | 124.6K |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.51 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $164,805,000.00 | $41,175,600.00 |
| Revenue This Year | $18.72 | N/A |
| Revenue Next Year | $14.62 | N/A |
| P/E Ratio | $152.33 | ★ N/A |
| Revenue Growth | ★ 52.21 | N/A |
| 52 Week Low | $2.37 | $1.57 |
| 52 Week High | $8.36 | $12.46 |
| Indicator | TLS | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 51.96 | 32.97 |
| Support Level | $3.92 | $4.30 |
| Resistance Level | $4.65 | $4.59 |
| Average True Range (ATR) | 0.36 | 0.36 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 38.97 | 2.56 |
Telos Corp offers technology solutions and services that empower and protect the world's security-conscious organizations. The company delivers efficient, adaptable, and secure solutions that protect people, organizations, and information across government and industry. The company conducts its business through two reportable and operating segments: Security Solutions and Secure Networks. The Security Solutions segment is focused on cybersecurity, cloud, and identity solutions, and secure messaging through Xacta, Telos AMHS, and Telos ID offerings. The Secure Networks segment provides secure networking architectures and solutions to customers through secure mobility solutions, network management, and defense services. The majority of revenue is from Secure Networks.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.